How Long Is COVID Contagious? Timeline & Tests

Most people with COVID-19 are contagious for roughly eight to ten days after symptoms appear, with viral shedding peaking right around or just before symptom onset. That window can shift meaningfully depending on vaccination status, immune health, antiviral treatment, and which variant is involved. Understanding when you’re actually infectious, as opposed to merely testing positive, matters because the two timelines are not the same. A PCR test can stay positive for weeks after you’ve stopped being a transmission risk, while a rapid antigen test tracks much more closely with the period when live virus is present.

The Peak and the Decline

The amount of live, transmissible virus in your upper respiratory tract peaks around the time symptoms first appear. A study of 324 samples from COVID patients in England found that infectious virus persisted for about ten days in mild-to-moderate cases, and the probability of culturing live virus dropped to just 6% by day ten after symptom onset.¹ A longitudinal study of 95 non-hospitalized adults found that the median time from symptom onset to a first negative viral culture was 11 days, with most people clearing culturable virus within two weeks.²

That same study illustrates why the type of test matters so much. The median time to a negative antigen test was 9 to 13 days depending on which antigen marker was measured, while viral RNA by PCR remained detectable in half the participants tested 21 to 30 days after symptom onset.² In practical terms, you could still “test positive” on a PCR three weeks in without carrying any live virus that could infect someone else.

Presymptomatic Spread and Why Timing Feels Unpredictable

One of the reasons COVID spread so effectively is that a substantial share of transmission happens before the infected person feels sick at all. A scoping review estimated that the presymptomatic infectious period ranged from less than one day to about four days across studies.³ Research on the Omicron variant in Italian households estimated that roughly half of all transmissions from symptomatic individuals occurred before those individuals noticed any symptoms.⁴

This is why contact tracing was so difficult early in the pandemic and why isolation guidance has always felt slightly after-the-fact. By the time you realize you’re sick, you may have already passed the virus to someone in your household or workplace. The household serial interval for Omicron, meaning the typical gap between when one household member develops symptoms and when the next one does, was about 2.4 days.⁴ That tight interval reflects how much of the transmission is happening in those first couple of days.

How Variants Changed the Timeline

The contagious window has not stayed fixed across variants. Research comparing Delta, Omicron BA.1, and BA.2 found that the viral kinetics sped up as the virus evolved. The time from exposure to peak viral load shortened with each successive variant: roughly 6.6 days for Delta, 5.9 days for BA.1, and 5.2 days for BA.2. Incubation periods followed the same pattern, shrinking from about 6 days for Delta down to 4.5 days for BA.2.⁵ The practical upshot is that later Omicron subvariants tend to produce a faster-in, faster-out infection cycle. You get sick sooner after exposure, hit peak contagiousness sooner, and likely clear the virus somewhat faster than you would have with earlier variants.

A rapid review covering studies through to 2025 found that for Omicron transmission pairs, at least 70% of secondary cases had symptom onset within five days of the primary case’s symptoms. By the end of day seven, at least 80% of secondary cases had appeared.⁶ This compressed timeline means the real-world contagious risk is heavily concentrated in the first week.

What Rapid Antigen Tests Actually Tell You

The rapid antigen tests you pick up at a pharmacy are not just convenient screening tools. They track contagiousness more reliably than PCR tests do. One study comparing antigen test results against viral culture found excellent agreement between a positive rapid antigen test and the ability to grow live virus from the same sample.⁷ Put simply: if a rapid test turns positive, you’re probably carrying enough live virus to infect someone. If it turns negative, there’s a good chance your contagious period is ending.

This tracks with what’s known about antigen detection windows. Patients with COVID tend to become undetectable for antigen at roughly 7 to 8 days after symptom onset, which lines up with the infectious period measured by viral culture.⁸ That’s in contrast to PCR, which can remain positive for two to three weeks or longer because it detects viral RNA fragments even after the virus is no longer viable.

A single rapid test can still miss an infection if you test too early. A prospective cohort study found that serial testing, two rapid tests separated by 48 hours, boosted sensitivity to about 93% among symptomatic people in the first week of illness. For asymptomatic people, three tests at 48-hour intervals were needed to achieve comparable performance.⁹ The takeaway: if you suspect exposure and your first rapid test is negative, test again in two days before you assume you’re in the clear.

Why PCR Positivity Doesn’t Mean Contagiousness

PCR tests amplify tiny amounts of genetic material, which makes them extraordinarily sensitive. That sensitivity is a double-edged sword for questions about contagiousness. A PCR test can flag viral RNA long after the immune system has dismantled the actual virus. In the longitudinal study of non-hospitalized adults mentioned earlier, half the participants still tested PCR-positive 21 to 30 days after symptom onset, at a point when almost none had culturable virus.²

Some researchers have tried to use the cycle threshold value from a PCR test, essentially how many amplification cycles are needed before virus is detected, as a proxy for how much virus is present. Higher cycle thresholds mean less viral material. One study found that the probability of culturing live virus dropped to 8% in samples with a cycle threshold above 35.¹ But translating cycle threshold values into a clean yes-or-no answer about contagiousness is unreliable. These values vary depending on the gene being tested, the assay manufacturer, the instrument used, and even the quality of the swab collection. A definitive single cutoff for infectivity cannot be defined.¹⁰ For everyday decisions about whether you’re still contagious, a rapid antigen test is more useful than a PCR result.

What Makes the Contagious Period Longer or Shorter

Several factors push the contagious window in one direction or the other. Vaccination, prior infection, disease severity, immune status, and antiviral treatment all play a role.

Vaccination appears to shorten the period of viral shedding, though the magnitude depends on the comparison group and the variant. One study found that vaccinated individuals had a median duration of PCR positivity of just 2 days, compared to 16.5 days in unvaccinated people with natural infections.¹¹ A Lancet study looking specifically at infectious viral load found that while peak viral load was similar between vaccinated and unvaccinated people, the decline rate of infectious virus was somewhat faster in vaccinated cases.¹² The picture here isn’t perfectly consistent across studies, but the general direction is clear: vaccination doesn’t prevent infection but it likely helps you clear the virus faster.

Disease severity also matters. A review found that the estimated mean time from symptom onset to two consecutive negative PCR tests was about 13.4 days, but this was shorter in studies that included children or less severe cases.³ Milder infections tend to resolve faster, as you’d expect.

Antiviral treatment with Paxlovid (nirmatrelvir/ritonavir) can substantially accelerate viral clearance when started early. One study found that patients treated with Paxlovid had a median viral elimination time of 5 days compared to 8 days in the untreated group, and those who started treatment within 3 days of symptom onset cleared the virus even faster, in a median of 4.5 days.¹³

Immunocompromised Patients and Prolonged Infectiousness

The standard ten-day window does not apply to everyone. People with severely weakened immune systems can remain infectious for weeks or even months. Three immunocompromised patients were documented shedding live, culturable virus for up to four months after symptom onset. One patient with complete immunosuppression had a single continuous infection with consistently high viral load and positive culture results spanning 123 days.¹⁴

Even more extreme cases have been documented. A retrospective study of patients with blood cancers and low antibody levels identified persistent infections lasting 269 and 305 days, with the virus accumulating mutations during that time, including mutations associated with variants of concern.¹⁵ These prolonged infections are rare but have implications beyond the individual patient. They represent environments where the virus can evolve under immune pressure, potentially generating new variants. For anyone who is immunocompromised, standard isolation timelines are insufficient, and repeated viral culture or antigen testing is the only reliable way to confirm the end of infectiousness.

Paxlovid Rebound and Its Effect on Contagiousness

Paxlovid rebound, where symptoms or viral load return after completing a five-day course of the drug, complicates the contagiousness timeline for a meaningful number of treated patients. About one in five patients who took Paxlovid experienced virologic rebound, compared to under 2% of untreated patients. Those with rebound had prolonged viral shedding that averaged 14 days, compared to fewer than 5 days in those who did not rebound.¹⁶

The leading explanation is that starting Paxlovid near symptom onset halts viral replication before the immune system has fully mounted its own response. The drug suppresses the virus effectively while being taken, but if it hasn’t been completely eliminated by the end of the five-day course, the remaining virus can rebound in the gap before the immune system catches up.¹⁷ Whether that rebound makes a person meaningfully contagious again is still being studied, but the presence of detectable virus strongly suggests some transmission risk. If you took Paxlovid and your symptoms return after finishing the course, treat yourself as potentially contagious again and test with a rapid antigen test before resuming normal activities.

Test-Based Strategies for Ending Isolation

If you’re trying to figure out when it’s safe to leave isolation, test-based approaches outperform fixed calendar approaches. A cost-effectiveness analysis modeled various exit strategies and found that ending isolation after a negative antigen test on day six produced the fewest secondary infections per 100 people, around 2.9, compared to 23 for a flat five-day isolation with no testing and about 17.8 for a symptom-check-only approach on day five.¹⁸

Another modeling study examined what it takes to keep the risk of leaving isolation prematurely below 5%. For symptomatic people, the safest approach was testing daily and observing two consecutive negative results before ending isolation. Under those conditions, the risk of premature release dropped to about 2.6%, with the average isolation burden at roughly four extra days beyond whatever minimum period was set.¹⁹ Two consecutive negatives is a stricter standard than most official guidance, but it’s the most defensible approach if you’re living with someone vulnerable.

The practical version of all this: isolate for at least five days from symptom onset. Starting on day five or six, take a rapid antigen test. If it’s negative, your risk of transmitting the virus is low. If it’s still positive, keep isolating and test again in 24 to 48 hours. Repeat until you get a negative result. If you’re immunocompromised or experienced Paxlovid rebound, extend that timeline and keep testing.

Reducing Transmission While You’re Still Contagious

Because so much transmission happens before or right at symptom onset, isolation alone can’t catch all of it. Masks remain one of the most effective tools for reducing spread during the contagious window. A meta-analysis of 29 studies on SARS-CoV-2, SARS, and MERS found that N95-type respirators, surgical masks, and multilayer cotton masks all substantially reduced infection risk for wearers, cutting it by roughly two-thirds.²⁰ The same analysis noted that when infections did occur despite mask use, they tended to be milder, likely because the mask reduced the initial dose of virus.

Ventilation and distance matter too, but masks are the intervention most within an individual’s control during those first few days of infection when viral load is highest and you may not yet know you’re sick. If you’ve been exposed to someone with COVID and are in the presymptomatic window, wearing a well-fitting mask around others is the single most effective precaution you can take until a rapid test either confirms or rules out infection. And if your rapid test does turn positive, continuing to mask in shared spaces, opening windows, and sleeping in a separate room from household members all reduce the odds of passing the virus along during the peak shedding days.

Asymptomatic Infections and Contagiousness

People who never develop symptoms still carry and shed the virus, and the data suggest they’re contagious for a similar period as symptomatic individuals. The England viral culture study found that the probability of culturing live virus was similar in asymptomatic and symptomatic persons.¹ This is one of the more frustrating aspects of COVID from a public health perspective: you can be perfectly contagious while feeling fine.

For asymptomatic infections, there’s no “symptom onset” date to count from, making the timeline murkier. If you test positive on a rapid antigen test with no symptoms, the safest approach is the same test-based strategy described above. Begin counting from the date of your first positive test, isolate, and use serial rapid antigen testing to determine when it’s safe to resume contact with others. Because asymptomatic people tend to seek testing only when they know they’ve been exposed or are required to test for travel or work, many asymptomatic infections go entirely undetected, and the contagious period passes without the person ever knowing they were a risk to others.

1
PubMed Central. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020
2
PubMed Central. Duration of viral infectiousness and correlation with symptoms and diagnostic testing in non-hospitalized adults during acute SARS-CoV-2 infection
3
BMJ Open. Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases
4
The Lancet Regional Health – Europe. Generation time and serial interval of the SARS-CoV-2 Omicron variant in Italy
5
PLoS Biology. Combined analyses of within-host SARS-CoV-2 viral kinetics and information on past exposures to the virus in a human cohort identifies intrinsic differences of Omicron and Delta variants
6
PubMed Central. Risk period for transmission of SARS-CoV-2 and seasonal influenza: a rapid review
7
PubMed Central. The Usefulness of Antigen Testing in Predicting Contagiousness in COVID-19
8
The Lancet Infectious Diseases. Diagnosing SARS-CoV-2 infection using rapid antigen tests
9
PubMed Central. Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2 Infection
10
Scientific Reports. Cycle threshold of SARS-CoV-2 RT-PCR as a driver of retesting
11
PLoS ONE. Lower probability and shorter duration of infections after COVID-19 vaccine correlate with anti-SARS-CoV-2 circulating IgGs
12
The Lancet Respiratory Medicine. Onset and dynamics of viral shedding in naturally acquired SARS-CoV-2 infection
13
PubMed Central. Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 Omicron variants
14
The Journal of Infectious Diseases. Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection
15
Clinical Infection in Practice. Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review
16
Annals of Internal Medicine. One in Five Patients Experience Rebound COVID After Taking Paxlovid, New Study Finds
17
PubMed Central. An explanation for SARS-CoV-2 rebound after Paxlovid treatment
18
PubMed Central. COVID-19 testing protocols to guide duration of isolation: a cost-effectiveness analysis
19
Nature Communications. Designing isolation guidelines for COVID-19 patients with rapid antigen tests
20
PubMed Central. Protection From COVID-19–The Efficacy of Face Masks